Tirzepatide vs Cagrilintide
Tirzepatide vs Cagrilintide: GLP-1 + GIP appetite control vs amylin pathway. Two different levers on hunger.
The verdict
Two separate hunger switches. Tirzepatide works GLP-1 plus GIP and is a proven, FDA-approved standalone. Cagrilintide works the amylin pathway and was really designed to pair with a GLP-1 (that's CagriSema), not to fly solo. As a single agent for weight loss, Tirzepatide is the far stronger and better-documented choice. Cagrilintide earns its keep as a complementary add-on, not as a head-to-head replacement.
Tirzepatide is the prescription weight-loss drug sold as Mounjaro (diabetes) or Zepbound (weight loss). It hits two appetite-control receptors at once. Most users lose 15-20% of body weight over several months. One injection per week.
Cagrilintide is an amylin agonist, a different appetite-control pathway than the GLP-1 drugs. Often paired with Semaglutide as 'CagriSema' for weight loss that breaks past GLP-1 plateaus. Once-weekly injection.
Which one should you pick?
Pick Tirzepatide if users who couldn't tolerate semaglutide or metabolic-syndrome adults under provider guidance.
Pick Cagrilintide if users plateaued on semaglutide or tirzepatide or people wanting cleaner satiety without bigger glp-1 nausea.
Still torn between Tirzepatide and Cagrilintide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.